生物活性结构用于人工智能对Candida auris聚合酶的抑制剂
Francisco Das Chagas Lima Pinto1, Sadrack Queque Cabongo2, Pedro Paulino João2
1Sociobiodiversity and Sustainable Technologies - MASTS, Institute of Engineering and Sustainable Development, University of International Integration of Afro-Brazilian Lusophony, Acarape-CE, Brazil.
研究人员使用人工智能开发了新型化合物来抑制C. 奥里斯 聚合酶. 该研究确定了一种有前途的化合物,Hit-960,用于潜在的新型抗真菌治疗.
科学领域:
- 计算化学是一种计算化学.
- 药物发现 药物发现
- 抗微生物耐药性 抗微生物耐药性
背景情况:
- 阳光候选物 (C. auris) 是一种 紫外线 (auris) 由于其多药性耐药性,构成了全球健康的重大威胁.
- 开发新型抑制剂对抗必需的C. 它的聚合酶,对于新的治疗策略至关重要.
研究的目的:
- 通过新的药物设计和人工智能 (AI) 设计的新生物活性化合物.
- 为了确定C.的潜在抑制剂. 奥里斯 聚合酶.
- 评估AI产生的化合物的治疗潜力与C. 黄金星. 黄金星. 黄金星.
主要方法:
- 利用MolaAICal的AI模块对FDA批准的分子碎片进行选,以检测C. 奥里斯 聚合酶抑制.
- 采用对接,分子动力学模拟和药物动力学预测来评估化合物的疗效和特性.
- 优化合成可访问性和结构复杂性为选定的候选人.
主要成果:
- 选了1,722种潜在的化合物,确定了Hit-960作为主要候选者.
- 希特-960表现出高生物亲和度和稳定性,结合能量为-9.12 kcal/mol.
- 为Hit-960化合物实现了75%的合成可访问性.
结论:
- 已识别的Hit-960化合物显示出作为C的抑制剂的显著潜力. 奥里斯 聚合酶.
- 建议进行进一步的临床研究,以验证Hit-960.的疗效.
- 这种人工智能驱动的方法有助于开发针对C的新型治疗策略. 病毒感染. 感染. 感染.
更多相关视频
11:44Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
Published on: January 19, 2022
10:17Methodologies for Studying B. subtilis Biofilms as a Model for Characterizing Small Molecule Biofilm Inhibitors
Published on: October 9, 2016
相关概念视频
Enzyme Inhibition
Enzymes
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
